Mark Lovern
Impact in
- Internal Medicine top 10%
- Molecular Medicine top 10%
- Antibiotic Resistance in Bacteria
Papers in
-
- Pharmaceutical studies and practices 6
-
- Antibiotics Pharmacokinetics and Efficacy 5
- Pharmacogenetics and Drug Metabolism 3
- Co-authors
- Todd A. Riccobene (4 shared papers)Timothy J. Carrothers (4 shared papers)Paul M. Schlosser (1 shared paper)Shampa Das (2 shared papers)Mats O. Karlsson (2 shared papers)Naab Al‐Saady (1 shared paper)Norman E. Lepor (1 shared paper)Xiaohui Wang (1 shared paper)
- Journals
- Clinical Pharmacology & Therapeutics (3 papers)Carcinogenesis (2 papers)Antimicrobial Agents and Chemotherapy (2 papers)Journal of the American Academy of Dermatology (1 paper)Journal of Chemotherapy (1 paper)
- Partner nations
- United StatesUnited KingdomSweden
In The Last Decade
Mark Lovern
22 papers receiving 539 citations
Peers
Comparison fields: 5 of 69
- Internal Medicine 25
- Molecular Medicine 54
- Pharmacology 104
- Genetics 41
- Pharmacology 37
Countries citing papers authored by Mark Lovern
This map shows the geographic impact of Mark Lovern's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Lovern with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Lovern more than expected).
Fields of papers citing papers by Mark Lovern
This network shows the impact of papers produced by Mark Lovern. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Lovern. The network helps show where Mark Lovern may publish in the future.
Co-authors
The 25 scholars most cited alongside Mark Lovern, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 23 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2018 | 84 | |
| 2 | 2021 | 83 | |
| 3 | 1997 | 50 | |
| 4 | 2009 | 49 | |
| 5 | 2002 | 47 | |
| 6 | 2022 | 47 | |
| 7 | 2021 | 37 | |
| 8 | 2001 | 36 | |
| 9 | 2011 | 29 | |
| 10 | 2020 | 27 | |
| 11 | 2021 | 25 | |
| 12 | 1999 | 18 | |
| 13 | 2023 | 12 | |
| 14 | 2009 | 5 | |
| 15 | 2022 | 5 | |
| 16 | 2014 | 3 | |
| 17 | 2017 | 3 | |
| 18 | 2023 | 3 | |
| 19 | 2019 | 2 | |
| 20 | 2010 | 1 |
About Mark Lovern
Mark Lovern is a scholar working on Pediatrics, Perinatology and Child Health, Pharmacology, Pharmacology, Hematology and Infectious Diseases, having authored 23 papers that have together received 568 indexed citations. Recurring topics across this work include Pharmaceutical studies and practices (6 papers), Antibiotics Pharmacokinetics and Efficacy (5 papers), Pharmacogenetics and Drug Metabolism (3 papers), Influenza Virus Research Studies (2 papers), HIV/AIDS drug development and treatment (2 papers), Blood Coagulation and Thrombosis Mechanisms (2 papers), Chronic Myeloid Leukemia Treatments (1 paper) and Hemophilia Treatment and Research (1 paper). The work is most often cited by research in Internal Medicine (25 citations), Molecular Medicine (54 citations), Pharmacology (104 citations), Genetics (41 citations) and Pharmacology (37 citations). Mark Lovern has collaborated with scholars based in United States, United Kingdom and Sweden. Frequent co-authors include Todd A. Riccobene, Timothy J. Carrothers, Paul M. Schlosser, Shampa Das, Mats O. Karlsson, Naab Al‐Saady, Norman E. Lepor, Xiaohui Wang, Constance Cullen and B. Alexander Yi. Their work appears in journals such as Clinical Pharmacology & Therapeutics, Carcinogenesis, Antimicrobial Agents and Chemotherapy, Journal of the American Academy of Dermatology and Journal of Chemotherapy.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.